Pollack H, Zhan M X, Safrit J T, Chen S H, Rochford G, Tao P Z, Koup R, Krasinski K, Borkowsky W
Department of Pediatrics, New York University Medical-Bellevue Hospital Center, NY 10016, USA.
AIDS. 1997 Jan;11(1):F9-13. doi: 10.1097/00002030-199701000-00002.
To study the role and development of non-cytotoxic CD8+ T-cell-mediated suppression of HIV replication in early perinatal HIV infection in a prospective study of vertically infected infants. CD8 T-cell-mediated HIV suppression was measured several times during the first year of life and correlated with viral load, cytotoxic T-cell (CTL) activity, in vitro antibody production (IVAP) and clinical outcome.
CD8+ T-cell-mediated HIV suppression was measured by comparing the amount of p24 antigen produced by endogenously infected lymphocytes with cultures of the same number of autologous CD4+ T cells from which CD8+ cells were removed immunomagnetically. CD8 viral suppressive activity (VSA) was defined as a > or = 50% reduction in p24 antigen in the cultures containing CD8+ cells.
CD8+ T-cell-mediated HIV VSA was detected in 11/16 infants in the first year of life, including six/nine infants studied before 6 months and as early as 3 weeks of age. Infants who demonstrated CD8 VSA had a lower early peak and 6-month 'setpoint' plasma HIV RNA concentration than infants who lacked CD8 VSA [1.51 versus 4.94 and 0.094 versus 0.639 x 10(6) copies/ml, respectively, and higher CD4 percentage at 1 year of age. Survival of infants lacking CD8 VSA (four/six were rapid progressors) was shorter than for infants who demonstrated CD8 VSA (none out of 10 were rapid progressors). CD8 VSA was present before CTL and before or at the same time as IVAP in two of two and 11 of 14 infants studied, respectively.
CD8+ T-cell-mediated VSA can be demonstrated in a large proportion of HIV-infected infants early in the course of infection. This non-cytolytic HIV-suppressive immune response appears to play an important protective role in the early control of perinatal HIV infection at a time when other immune responses are either absent or deficient.
在一项针对垂直感染婴儿的前瞻性研究中,探讨非细胞毒性CD8 + T细胞介导的对围产期早期HIV复制抑制作用及其发展情况。在生命的第一年中多次测量CD8 T细胞介导的HIV抑制作用,并将其与病毒载量、细胞毒性T细胞(CTL)活性、体外抗体产生(IVAP)及临床结局相关联。
通过比较内源性感染淋巴细胞产生的p24抗原量与去除了CD8 +细胞的相同数量自体CD4 + T细胞培养物产生的p24抗原量,来测量CD8 + T细胞介导的HIV抑制作用。CD8病毒抑制活性(VSA)定义为含CD8 +细胞的培养物中p24抗原减少≥50%。
在生命的第一年中,16例婴儿中有11例检测到CD8 + T细胞介导的HIV VSA,其中9例在6个月前接受研究的婴儿中有6例,最早在3周龄时检测到。表现出CD8 VSA的婴儿早期峰值及6个月时的血浆HIV RNA “设定点”浓度低于未表现出CD8 VSA的婴儿[分别为1.51对4.94以及0.094对0.639×10(6)拷贝/毫升],且1岁时CD4百分比更高。未表现出CD8 VSA的婴儿(6例中有4例是快速进展者)的生存期短于表现出CD8 VSA的婴儿(10例中无快速进展者)。在分别研究的2例婴儿中的2例以及14例婴儿中的11例中,CD8 VSA在CTL之前以及在IVAP之前或与之同时出现。
在感染过程早期,很大比例的HIV感染婴儿中可证明存在CD8 + T细胞介导的VSA。这种非细胞溶解性的HIV抑制性免疫反应在围产期HIV感染的早期控制中似乎起着重要的保护作用,而此时其他免疫反应要么不存在,要么存在缺陷。